Vaxcell-Bio Therapeutics Co., Ltd.
Financials
Valuation Metrics
Vaxcell-Bio Therapeutics Co., Ltd.'s Market Cap is ₩927B. At end of 2025 it was ₩2323B. Ranked #1305 of 2,410 in KR market (top 54%), #716 of 1,631 on KOSDAQ (top 44%), #144 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 92.68B KRW | KR#1,305/2,410 Sec#144/231 |
| Revenue | 6.51B KRW | KR#2,309/2,410 Sec#186/231 |
| Net Income | -14.92B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 66.90B KRW | KR#2,041/2,410 Sec#173/231 |
| Net Assets | 61.13B KRW | KR#1,773/2,410 Sec#151/231 |
| Employees | 81 | KR#1,799/2,410 Sec#150/231 |
| Value | ||
| P/B | 1.52x | KR#1,800/2,410 Sec#127/231 |
| P/S | 14.23x | KR#2,309/2,410 Sec#176/231 |
| FCF Yield | -17.99% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -24.40% | KR#2,127/2,410 Sec#166/231 |
| ROA | -22.30% | KR#2,254/2,410 Sec#182/231 |
| Op. Margin | -257.06% | KR#2,331/2,410 Sec#190/231 |
| Revenue Growth | 17.35% | KR#612/2,410 Sec#56/231 |
| Financial Health | ||
| Debt Ratio | 9.44% | KR#124/2,410 Sec#27/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -16.67B KRW | KR#1,844/2,410 Sec#174/231 |
| Cash | 6.22B KRW | KR#1,918/2,410 Sec#171/231 |
| Current Ratio | 5.56x | KR#245/2,410 Sec#46/231 |
| Performance | ||
| 1Y Return | -57.10% | KR#2,147/2,410 Sec#198/231 |
| 1M Return | -7.00% | KR#1,374/2,410 Sec#140/231 |
| From 52W High | -65.41% | KR#1,971/2,410 Sec#167/231 |
| 1Y MDD | -67.41% | KR#1,821/2,410 Sec#153/231 |
| Trading | ||
| Volume | 94,197 shares | KR#1,071/2,410 Sec#108/231 |
| Trading Value | 373.8M KRW | KR#1,270/2,410 Sec#135/231 |
| Foreign Own. | 5.58% | KR#780/2,410 Sec#72/231 |
| Per Share | ||
| EPS | -641 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,628 KRW | KR#1,945/2,410 Sec#153/231 |
Company Info
Established in 2010 as a specialized company for developing anticancer immunotherapeutics, the company was listed on the KOSDAQ market in 2020. It has built diverse pipelines, including the innate immune system-based Vax-NK anticancer immunotherapy platform, the next-generation Vax-CAR series platform, small molecule compound targeted anticancer drugs, bispecific antibody new drugs, DDS-based drug development, and a pet healthcare business. The company continuously innovates to realize its vision of a better world through immunotherapies, focusing on key elements of the immune system. Vaxcell-Bio was established in 2010 and is headquartered in Jeollanam-do, Hwasun-gun.